Want to see HK:8329 full AI Analyst Report?
Top Page
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H
(8329)
Select Model
Select Model
Rating:54Neutral
Price Target:
HK$0.10
▼(-37.50% Downside)
Action:Reiterated
Date:09/07/26
The score is mainly held back by weak profitability (net losses and margin compression) despite a low-leverage balance sheet and strong recent cash generation. Technical indicators are also bearish (price below key moving averages and negative MACD), partially offset by a relatively attractive dividend yield.
Positive Factors
Low leverage
Low leverage gives the company financial flexibility while profitability is being repaired. Limited debt exposure reduces the burden of interest and refinancing obligations, allowing more operating cash to support investment, liquidity, or recovery efforts over the next several quarters.
Negative Factors
Recurring net losses
Net losses across 2025 and the TTM period show that revenue growth is not yet translating into sustainable earnings. Negative operating profit weakens earnings quality and, if prolonged, could reduce equity and constrain the company’s ability to reinvest from internally generated profits.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Low leverage gives the company financial flexibility while profitability is being repaired. Limited debt exposure reduces the burden of interest and refinancing obligations, allowing more operating cash to support investment, liquidity, or recovery efforts over the next several quarters.
Read all positive factors
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H (8329) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$164.44M
Dividend Yield5.48%
Average Volume (3M)322.00K
Price to Earnings (P/E)―
Beta (1Y)0.18
Revenue Growth-5.00%
EPS Growth-976.92%
CountryHK
Employees1,321
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.03
Shares Outstanding426,000,000
10 Day Avg. Volume290,000
30 Day Avg. Volume322,000
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.37
Price to Sales (P/S)0.25
P/FCF Ratio1.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H Business Overview & Revenue Model
Company Description
Based in Shenzhen, People's Republic of China, Shenzhen Neptunus Interlong Bio-technique Company Limited and its subsidiaries are primarily engaged in the research, development, production, and sale of pharmaceuticals. The company also handles the...
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H Financial Statement Overview
Summary
Income Statement
41
Neutral
Balance Sheet
70
Positive
Cash Flow
63
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.12B | 972.01M | 1.04B | 1.06B | 986.69M | 838.80M |
| Gross Profit | 326.93M | 287.22M | 328.04M | 439.24M | 444.14M | 374.10M |
| EBITDA | 48.44M | 48.10M | 62.87M | 69.89M | 125.24M | 73.97M |
| Net Income | -49.34M | -40.74M | 25.01M | 24.13M | 54.35M | 35.96M |
Balance Sheet | ||||||
| Total Assets | 1.07B | 1.06B | 1.40B | 1.42B | 1.45B | 1.31B |
| Cash, Cash Equivalents and Short-Term Investments | 212.22M | 209.45M | 283.42M | 382.21M | 350.10M | 311.14M |
| Total Debt | 96.37M | 73.02M | 105.43M | 89.69M | 92.69M | 105.69M |
| Total Liabilities | 359.20M | 352.70M | 371.99M | 399.46M | 442.93M | 363.17M |
| Stockholders Equity | 654.38M | 647.73M | 933.18M | 908.17M | 884.04M | 829.70M |
Cash Flow | ||||||
| Free Cash Flow | 132.87M | 124.95M | 2.20M | 38.32M | 41.51M | -85.00M |
| Operating Cash Flow | 144.90M | 139.59M | 24.41M | 53.69M | 61.22M | -69.92M |
| Investing Cash Flow | -14.64M | 83.26M | -114.62M | 60.90M | 10.76M | -181.57M |
| Financing Cash Flow | -24.72M | -306.92M | 1.43M | -32.48M | -9.02M | 66.75M |
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H Technical Analysis
Negative
0.16
Price Trends
0.11
Negative
0.11
Negative
0.13
Negative
Market Momentum
>-0.01
Positive
41.10
Neutral
25.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8329, the sentiment is Negative. The current price of 0.16 is above the 20-day moving average (MA) of 0.11, above the 50-day MA of 0.11, and above the 200-day MA of 0.13, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 41.10 is Neutral, neither overbought nor oversold. The STOCH value of 25.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:8329.
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
87 Outperform | HK$1.29B | 3.92 | 15.91% | 11.31% | 0.20% | 24.13% | |
71 Outperform | HK$1.25B | 4.69 | 10.70% | 5.53% | -0.74% | -15.21% | |
60 Neutral | HK$19.66B | 155.39 | 1.43% | ― | -8.55% | -96.20% | |
54 Neutral | HK$164.44M | -2.86 | -7.58% | 5.48% | -5.00% | -976.92% | |
53 Neutral | HK$13.09B | 351.50 | 0.82% | 1.31% | 38.42% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$11.54B | -80.00 | -253.66% | ― | ― | ― |
* Healthcare Sector Average
HK:8329
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H
0.10
-0.06
-37.42%
HK:0013
HUTCHMED (China)
22.38
-2.82
-11.19%
HK:1061
Essex Bio-Technology
2.17
-2.78
-56.17%
HK:8049
Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H
2.31
0.43
23.00%
HK:6185
CanSino Biologics, Inc. Class H
28.50
-26.25
-47.95%
HK:2627
Ab&B Bio-Tech CO., LTD. JS Class H
29.32
-17.26
-37.05%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.